Clinical Trial Detail

NCT ID NCT02764333
Title TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

peritoneal carcinoma

ovarian carcinoma

fallopian tube carcinoma

Therapies

Durvalumab + TPIV 200

Age Groups: adult

No variant requirements are available.